Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!
Ajanta Pharma Yönetim
Yönetim kriter kontrolleri 1/4
Şu anda CEO hakkında yeterli bilgiye sahip değiliz.
Anahtar bilgiler
Yogesh Agrawal
İcra Kurulu Başkanı
₹216.0m
Toplam tazminat
| CEO maaş yüzdesi | 57.2% |
| CEO görev süresi | 16.8yrs |
| CEO sahipliği | 14.4% |
| Yönetim ortalama görev süresi | Veri yok |
| Yönetim Kurulu ortalama görev süresi | 6yrs |
Son yönetim güncellemeleri
Recent updates
Here's Why Ajanta Pharma (NSE:AJANTPHARM) Has Caught The Eye Of Investors
Sep 10
We Think Ajanta Pharma (NSE:AJANTPHARM) Can Manage Its Debt With Ease
Aug 23Ajanta Pharma Limited Just Recorded A 11% EPS Beat: Here's What Analysts Are Forecasting Next
Aug 04Some Confidence Is Lacking In Ajanta Pharma Limited's (NSE:AJANTPHARM) P/E
Aug 01With EPS Growth And More, Ajanta Pharma (NSE:AJANTPHARM) Makes An Interesting Case
Jun 01Ajanta Pharma Limited (NSE:AJANTPHARM) Analysts Are Pretty Bullish On The Stock After Recent Results
May 05Ajanta Pharma Limited's (NSE:AJANTPHARM) Intrinsic Value Is Potentially 23% Below Its Share Price
Apr 05We Think Ajanta Pharma (NSE:AJANTPHARM) Can Manage Its Debt With Ease
Feb 23Ajanta Pharma Limited (NSE:AJANTPHARM) Investors Are Less Pessimistic Than Expected
Dec 23Ajanta Pharma (NSE:AJANTPHARM) Seems To Use Debt Quite Sensibly
Aug 26These 4 Measures Indicate That Ajanta Pharma (NSE:AJANTPHARM) Is Using Debt Reasonably Well
Feb 07Here's Why Ajanta Pharma (NSE:AJANTPHARM) Has Caught The Eye Of Investors
Oct 24Estimating The Intrinsic Value Of Ajanta Pharma Limited (NSE:AJANTPHARM)
Aug 25Is Now The Time To Put Ajanta Pharma (NSE:AJANTPHARM) On Your Watchlist?
Jul 19A Look At The Intrinsic Value Of Ajanta Pharma Limited (NSE:AJANTPHARM)
Apr 28Ajanta Pharma (NSE:AJANTPHARM) Seems To Use Debt Quite Sensibly
Mar 14I Built A List Of Growing Companies And Ajanta Pharma (NSE:AJANTPHARM) Made The Cut
Feb 06Estimating The Fair Value Of Ajanta Pharma Limited (NSE:AJANTPHARM)
Dec 13Ajanta Pharma (NSE:AJANTPHARM) Will Pay A Dividend Of ₹9.50
Oct 31Here's Why We Think Ajanta Pharma (NSE:AJANTPHARM) Is Well Worth Watching
Sep 22Is Ajanta Pharma Limited (NSE:AJANTPHARM) Trading At A 27% Discount?
Sep 08Does Ajanta Pharma (NSE:AJANTPHARM) Have A Healthy Balance Sheet?
Aug 26Here's Why Shareholders Will Not Be Complaining About Ajanta Pharma Limited's (NSE:AJANTPHARM) CEO Pay Packet
Jul 07Should You Be Adding Ajanta Pharma (NSE:AJANTPHARM) To Your Watchlist Today?
Jun 14Is Ajanta Pharma Limited (NSE:AJANTPHARM) Trading At A 30% Discount?
May 15Ajanta Pharma Limited (NSE:AJANTPHARM) Vies For A Place In Your Dividend Portfolio: Here's Why
Apr 10Ajanta Pharma Limited's (NSE:AJANTPHARM) Has Had A Decent Run On The Stock market: Are Fundamentals In The Driver's Seat?
Mar 11Does Ajanta Pharma (NSE:AJANTPHARM) Deserve A Spot On Your Watchlist?
Feb 24The Ajanta Pharma (NSE:AJANTPHARM) Share Price Is Up 56% And Shareholders Are Holding On
Jan 30
What Can We Make Of Ajanta Pharma's (NSE:AJANTPHARM) CEO Compensation?
Jan 18Estimating The Fair Value Of Ajanta Pharma Limited (NSE:AJANTPHARM)
Jan 06What Percentage Of Ajanta Pharma Limited (NSE:AJANTPHARM) Shares Do Insiders Own?
Dec 25CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | ₹9b |
| Mar 31 2024 | ₹216m | ₹124m | ₹8b |
| Dec 31 2023 | n/a | n/a | ₹7b |
| Sep 30 2023 | n/a | n/a | ₹7b |
| Jun 30 2023 | n/a | n/a | ₹6b |
| Mar 31 2023 | ₹156m | ₹112m | ₹6b |
| Dec 31 2022 | n/a | n/a | ₹6b |
| Sep 30 2022 | n/a | n/a | ₹7b |
| Jun 30 2022 | n/a | n/a | ₹7b |
| Mar 31 2022 | ₹163m | ₹94m | ₹7b |
| Dec 31 2021 | n/a | n/a | ₹7b |
| Sep 30 2021 | n/a | n/a | ₹7b |
| Jun 30 2021 | n/a | n/a | ₹7b |
| Mar 31 2021 | ₹128m | ₹75m | ₹7b |
| Dec 31 2020 | n/a | n/a | ₹6b |
| Sep 30 2020 | n/a | n/a | ₹6b |
| Jun 30 2020 | n/a | n/a | ₹5b |
| Mar 31 2020 | ₹107m | ₹66m | ₹5b |
| Dec 31 2019 | n/a | n/a | ₹4b |
| Sep 30 2019 | n/a | n/a | ₹4b |
| Jun 30 2019 | n/a | n/a | ₹4b |
| Mar 31 2019 | ₹99m | ₹61m | ₹4b |
| Dec 31 2018 | n/a | n/a | ₹4b |
| Sep 30 2018 | n/a | n/a | ₹5b |
| Jun 30 2018 | n/a | n/a | ₹5b |
| Mar 31 2018 | ₹44m | ₹13m | ₹5b |
Tazminat ve Piyasa: Yogesh 'nin toplam tazminatı ($USD 2.58M ), Indian pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 637.49K ).
Tazminat ve Kazançlar: Yogesh 'in maaşı son bir yılda %20'den fazla arttı.
CEO
Yogesh Agrawal (52 yo)
16.8yrs
Görev süresi
₹215,960,000
Tazminat
Mr. Yogesh Mannalal Agrawal, M.B.A, has been Managing Director at Ajanta Pharma Ltd. since December 14, 2007. Mr. Agrawal is handling global business of Ajanta Pharma Ltd.He has handled various aspects of...
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| MD & Executive Director | 24.5yrs | ₹215.96m | 14.42% ₹ 60.1b | |
| Joint MD & Director | 11.5yrs | ₹215.96m | 14.42% ₹ 60.1b | |
| Executive Vice Chairman of the Board | 26.8yrs | ₹42.04m | Veri yok | |
| Director of Ajanta Pharma USA Inc. | no data | ₹25.50m | Veri yok | |
| Chairman of the Board | 44.8yrs | ₹777.00k | Veri yok | |
| Independent Non-Executive Director | less than a year | Veri yok | Veri yok | |
| Independent Non-Executive Director | less than a year | Veri yok | Veri yok | |
| Director of Ajanta Pharma Philippines Inc. | no data | Veri yok | Veri yok | |
| Director of Ajanta Pharma (Mauritius) Ltd. | no data | Veri yok | Veri yok | |
| Director of Ajanta Pharma (Mauritius) Ltd. | no data | Veri yok | Veri yok | |
| Independent Non-Executive Director | less than a year | Veri yok | Veri yok | |
| Independent Non-Executive Director | less than a year | Veri yok | Veri yok |
6.0yrs
Ortalama Görev Süresi
68yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: AJANTPHARM 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 6 yıldır).